These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38347222)

  • 1. Large-scale functional network connectivity mediates the association between nigral neuromelanin hypopigmentation and motor impairment in Parkinson's disease.
    Yan S; Lu J; Li Y; Zhu H; Tian T; Qin Y; Zhu W
    Brain Struct Funct; 2024 May; 229(4):843-852. PubMed ID: 38347222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
    Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
    Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.
    Martín-Bastida A; Lao-Kaim NP; Roussakis AA; Searle GE; Xing Y; Gunn RN; Schwarz ST; Barker RA; Auer DP; Piccini P
    Brain; 2019 Jul; 142(7):2023-2036. PubMed ID: 31056699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia.
    Su D; Gan Y; Zhang Z; Cui Y; Zhang Z; Liu Z; Wang Z; Zhou J; Sossi V; Stoessl AJ; Wu T; Jing J; Feng T
    Mov Disord; 2023 Apr; 38(4):616-625. PubMed ID: 36799459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor asymmetry and neuromelanin imaging: Concordance in Parkinson's disease.
    Prasad S; Saini J; Yadav R; Pal PK
    Parkinsonism Relat Disord; 2018 Aug; 53():28-32. PubMed ID: 29709506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional nigral neuromelanin degeneration in asymptomatic leucine-rich repeat kinase 2 gene carrier using MRI.
    Gao L; Gaurav R; Ziegner P; Ma J; Sun J; Chen J; Fang J; Fan Y; Bao Y; Zhang D; Chan P; Yang Q; Fan Z; Lehéricy S; Wu T
    Sci Rep; 2024 May; 14(1):10621. PubMed ID: 38729969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI.
    Liu Q; Wang P; Liu C; Xue F; Wang Q; Chen Y; Hou R; Chen T
    BMC Neurol; 2023 Aug; 23(1):301. PubMed ID: 37580712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
    Kashihara K; Shinya T; Higaki F
    J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.